Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 crawled time : 13:30 save search
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $27.2 -2.61% 75K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | News | $0.704 -5.55% 540K
|
Health Technology
|
| O: 2.1%
H: 1.04%
C: -8.52%
covid-19 award candidate vaccine million nextgen study
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.43 -6.54% 590K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.429 0.28% 130K
|
Health Technology
|
| O: 6.63%
H: 12.99%
C: 6.78%
rhb-107 covid-19 funding study phase 2
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
NVAX | $4.115 -1.79% 1.1M
|
Health Technology
|
| O: -0.78%
H: 2.5%
C: 1.09%
covid-19 vaccine prototype approval
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
Published: 2023-10-13 (Crawled : 13:30) - prnewswire.com
NVAX | $4.115 -1.79% 1.1M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: -4.73%
covid-19 vaccine retail
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Published: 2023-10-03 (Crawled : 13:30) - biospace.com/
GILD | $67.03 2.4M
|
Health Technology
|
| O: -1.2%
H: 0.9%
C: 0.08%
covid-19 hiv
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
Published: 2023-09-11 (Crawled : 13:30) - globenewswire.com
GOVX | $1.54 6K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -5.53%
covid-19 vaccine trial phase 2
Cue Health and Albertsons Companies Partner to Provide Customers with Fast and Highly Accurate COVID-19 Testing in Pharmacies Across the U.S.
Published: 2022-03-22 (Crawled : 13:30) - prnewswire.com
HLTH | $0.153 2.0% 180K
|
|
| O: 1.32%
H: 0.87%
C: -7.07%
ACI | $20.325 0.03% 610K
|
Retail Trade
|
| O: 0.44%
H: 0.55%
C: -1.68%
covid-19 health companies
Cue Health's Pioneering Smart Home Lab and PCR-quality COVID-19 Test Now Available in Canada
Published: 2022-03-16 (Crawled : 13:30) - prnewswire.com
HLTH | $0.153 2.0% 180K
|
|
| O: -0.12%
H: 5.84%
C: 5.47%
covid-19 health covid one test smart
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
ABBV | News | $168.51 -0.61% 920K
|
Health Technology
|
| O: 0.11%
H: 2.74%
C: 2.38%
covid-19 treatment research covid collaboration antiviral
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 als phase 2/3 covid
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
RSSS 4 | $3.0 580
|
Commercial Services
|
| O: 1.07%
H: 1.71%
C: 1.25%
GOVX | $1.54 6K
|
Health Technology
|
| O: 0.0%
H: 1.35%
C: -4.73%
covid-19 phase 2 als trials trial covid clinical trials vaccine
Industrial Automation Market Worth $306.2 Billion by 2027 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Published: 2022-03-14 (Crawled : 13:30) - prnewswire.com
ROK | News | $277.19 0.31% 120K
|
Producer Manufacturing
|
| O: 1.16%
H: 0.7%
C: -1.4%
HON | News M | $194.77 -0.71% 830K
|
Producer Manufacturing
|
| O: -1.64%
H: 0.0%
C: 0.0%
covid-19 research trial covid report
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
Published: 2022-03-11 (Crawled : 13:30) - biospace.com/
IMNM | $14.55 -0.75% 230K
|
Health Technology
|
| O: 8.0%
H: 0.0%
C: 0.0%
bcp-01 clinical hold covid-19 treatment fda application covid
3D Printers Market worth $23.9 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Published: 2022-03-10 (Crawled : 13:30) - prnewswire.com
HPQ | $28.37 2.53% 8.5M
|
Electronic Technology
|
| O: -1.98%
H: 1.32%
C: 1.26%
DDD F | $3.46 -1.14% 460K
|
Producer Manufacturing
|
| O: -0.4%
H: 0.94%
C: 0.61%
covid-19 research covid report
3D Printing Materials Market Worth $9.86 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Published: 2022-03-08 (Crawled : 13:30) - prnewswire.com
HPQ | $28.37 2.53% 8.5M
|
Electronic Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
DDD F | $3.46 -1.14% 460K
|
Producer Manufacturing
|
| O: 0.14%
H: 5.28%
C: -0.27%
MTLS | $5.29 2.32% 27K
|
Technology Services
|
| O: 2.81%
H: 7.75%
C: 2.89%
covid-19 research als covid report
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
IPIX | $0.0042 92.86% 1.4K
|
Manufacturing
|
| O: -2.26%
H: 8.72%
C: -5.13%
covid-19 phase 2 als trial trial results covid report results
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Published: 2022-02-28 (Crawled : 13:30) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 1.62%
H: 3.23%
C: 1.6%
covid-19 treatment als covid enroll
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.